SLC5A2 and heart failure: In dapagliflozin-treated compared with vehicle-treated heart-failure rats, the calculated rates of myocardial VFA+AA/VCS were numerically higher in both the ischemic/infarct and nonischemic regions (Supplemental Figure 4, D and E), which paralleled their increase in plasma NEFA during SGLT2 inhibition.